专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140113890A1 NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION 有权
标题翻译：作为病毒复制的新型4-氨基-4-氧代戊酸酯
公开(公告)号：US20140113890A1
公开(公告)日：2014-04-24
申请号：US14139196
申请日：2013-12-23
申请人： Avinash Phadke , Dawei Chen , Venkat Gadhachanda , Akihiro Hashimoto , Godwin Pais , Xiangzhu Wang , Atul Agarwal , Ha Young Kim , Shuoming Li , Cuixian Liu , Suoming Zhang , Milind Deshpande
发明人： Avinash Phadke , Dawei Chen , Venkat Gadhachanda , Akihiro Hashimoto , Godwin Pais , Xiangzhu Wang , Atul Agarwal , Ha Young Kim , Shuoming Li , Cuixian Liu , Suoming Zhang , Milind Deshpande
IPC分类号： C07D207/16 , C07D401/14 , C07D413/14 , C07D417/12 , C07D409/14 , C07D491/113 , C07D487/18 , C07D417/14 , C07D401/12 , C07D403/12
CPC分类号： C07D207/16 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/08 , C07D487/08 , C07D487/18 , C07D491/113
摘要： The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.
摘要翻译：本发明提供式I的4-氨基-4-氧代丁酰基肽及其药学上可接受的盐和水合物。变量R，R1，R6-R8，R16，R18，R19，M，n，T，Y和Z在本文中定义。某些式I化合物可用作抗病毒剂。本文公开的4-氨基-4-氧代丁酰基肽是有效和/或选择性的病毒复制抑制剂，特别是丙型肝炎病毒复制。本发明还提供含有一种或多种4-氨基-4-氧代丁酰基肽和一种或多种药学上可接受的载体的药物组合物。这样的药物组合物可以含有4-氨基-4-氧代丁酰基肽作为唯一的活性剂，或者可以含有4-氨基-4-氧代丁酰基肽和一种或多种其它药物活性剂的组合。本发明还提供了治疗病毒感染的方法，包括丙型肝炎感染。

2. 发明授权

US08445430B2 Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus 失效
标题翻译：环丙酰胺化合物及其类似物作为丙型肝炎病毒
公开(公告)号：US08445430B2
公开(公告)日：2013-05-21
申请号：US12622753
申请日：2009-11-20
申请人： Suoming Zhang , Avinash Phadke , Milind Deshpande , Venkat Gadhachanda
发明人： Suoming Zhang , Avinash Phadke , Milind Deshpande , Venkat Gadhachanda
IPC分类号： A61K38/00 , A01N37/18
CPC分类号： C07K5/0808 , C07K5/0819
摘要： The invention provides cyclic carboxamide compounds and analogues thereof of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain cyclic carboxamide compounds and cyclic carboxamide analogues disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more cyclic carboxamide compounds or cyclic carboxamide analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a cyclic carboxamide compound or cyclic carboxamide analogue as the only active agent or may contain a combination of a cyclic carboxamide compound or cyclic carboxamide analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.
摘要翻译：本发明提供式I的环状羧酰胺化合物及其类似物及其药学上可接受的盐和水合物。变量R，R1，R6-R8，R16，R18，R19，M，n，T，Y和Z在本文中定义。某些式I化合物可用作抗病毒剂。本文公开的某些环状羧酰胺化合物和环状羧酰胺类似物是有效和/或选择性的病毒复制抑制剂，特别是丙型肝炎病毒复制。本发明还提供含有一种或多种环状羧酰胺化合物或环状甲酰胺类似物和一种或多种药学上可接受的载体的药物组合物。这样的药物组合物可以含有环状羧酰胺化合物或环状羧酰胺类似物作为唯一的活性剂，或者可以含有环状羧酰胺化合物或环状甲酰胺类似物和一种或多种其它药学活性剂的组合。本发明还提供了治疗病毒感染的方法，包括丙型肝炎感染。

3. 发明授权

US08173636B2 Hydroxylthienoquinolones and related compounds as anti-infective agents 失效
标题翻译：羟基噻吩并喹啉酮和相关化合物作为抗感染剂
公开(公告)号：US08173636B2
公开(公告)日：2012-05-08
申请号：US12754057
申请日：2010-04-05
申请人： Barton James Bradbury , Milind Deshpande , Akihiro Hashimoto , Ha Young Kim , Edlaine Lucien , Godwin Pais , Michael Pucci , Qiuping Wang , Jason Allan Wiles , Avinash Phadke
发明人： Barton James Bradbury , Milind Deshpande , Akihiro Hashimoto , Ha Young Kim , Edlaine Lucien , Godwin Pais , Michael Pucci , Qiuping Wang , Jason Allan Wiles , Avinash Phadke
IPC分类号： C07D495/04 , A61K31/4743 , A61K31/496
CPC分类号： A61K31/4743 , A61K31/496 , C07D495/04 , C07D498/16 , C07D519/00
摘要： Disclosed herein are hydroxylthienoquinolones and related compounds and their pharmaceutically acceptable salts useful as antiviral agents and having the general formula in which the variables R2, R6, and R7 are defined herein. Certain compounds provided herein possess potent antibacterial, antiprotozoal, or antifungal activity and are particularly efficacious for the treatment of MRSA infections. The invention also provides pharmaceutical compositions, pharmaceutical compositions containing a hydroxylthienoquinolone in combination with one or more other active agent, and methods of treating microbial infections in animals by administering an effective amount of a hydroxylthienoquinolone or related compound to an animal suffering from a microbial infection.
摘要翻译：本文公开的是羟基噻吩并喹啉酮和相关化合物及其药学上可接受的盐，其可用作抗病毒剂并具有通式，其中变量R2，R6和R7在本文中定义。本文提供的某些化合物具有有效的抗细菌，抗原生动物或抗真菌活性，并且对于治疗MRSA感染特别有效。本发明还提供药物组合物，含有羟基噻吩并喹啉与一种或多种其它活性剂的药物组合物，以及通过向有微生物感染的动物施用有效量的羟基噻吩并喹啉酮或相关化合物来治疗动物微生物感染的方法。

4. 发明授权

US08163693B2 Urea-containing peptides as inhibitors of viral replication 失效
标题翻译：含尿素肽作为病毒复制的抑制剂
公开(公告)号：US08163693B2
公开(公告)日：2012-04-24
申请号：US12236855
申请日：2008-09-24
申请人： Dawei Chen , Milind Deshpande , Avinash Phadke
发明人： Dawei Chen , Milind Deshpande , Avinash Phadke
IPC分类号： A61K38/00
CPC分类号： C07K5/0823 , A61K38/00 , C07K5/06165
摘要： The invention provides compounds urea-containing peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables T, R1-R9, J, L, M, Y, Z, m, n, and t are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain urea-containing peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more urea containing peptides compounds and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such pharmaceutical compositions may contain a urea containing peptides compound as the only active agent or may contain a combination of a urea containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
摘要翻译：本发明提供式I化合物的含脲的肽化合物及其药用盐和水合物。变量T，R1-R9，J，L，M，Y，Z，m，n和t在本文中定义。某些式I化合物可用作抗病毒剂。本文公开的某些含脲的肽化合物是病毒复制的有效和/或选择性抑制剂，特别是丙型肝炎病毒复制。本发明还提供含有一种或多种含尿素的肽化合物和一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。这样的药物组合物可以含有含有肽化合物作为唯一活性剂的尿素，或者可以含有含尿素的肽化合物和一种或多种其它药学活性剂的组合。本发明还提供了用于治疗哺乳动物中的病毒感染（包括丙型肝炎感染）的方法。

5. 发明申请

US20100256112A1 HYDROXYTHIENOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS 失效
标题翻译：羟肟酸和相关化合物作为抗感染剂
公开(公告)号：US20100256112A1
公开(公告)日：2010-10-07
申请号：US12754057
申请日：2010-04-05
申请人： Barton James BRADBURY , Milind DESHPANDE , Akihiro HASHIMOTO , Ha Young KIM , Edlaine LUCIEN , Godwin PAIS , Michael PUCCI , Qiuping WANG , Jason Allan WILES , Avinash PHADKE
发明人： Barton James BRADBURY , Milind DESHPANDE , Akihiro HASHIMOTO , Ha Young KIM , Edlaine LUCIEN , Godwin PAIS , Michael PUCCI , Qiuping WANG , Jason Allan WILES , Avinash PHADKE
IPC分类号： A61K31/4743 , C07D495/04 , A61K31/496 , A61P31/04
CPC分类号： A61K31/4743 , A61K31/496 , C07D495/04 , C07D498/16 , C07D519/00
摘要： Disclosed herein are hydroxylthienoquinolones and related compounds and their pharmaceutically acceptable salts useful as antiviral agents and having the general formula in which the variables R2, R6, and R7 are defined herein. Certain compounds provided herein possess potent antibacterial, antiprotozoal, or antifungal activity and are particularly efficacious for the treatment of MRSA infections. The invention also provides pharmaceutical compositions, pharmaceutical compositions containing a hydroxylthienoquinolone in combination with one or more other active agent, and methods of treating microbial infections in animals by administering an effective amount of a hydroxylthienoquinolone or related compound to an animal suffering from a microbial infection.
摘要翻译：本文公开的是羟基噻吩并喹啉酮和相关化合物及其药学上可接受的盐，其可用作抗病毒剂并具有通式，其中变量R2，R6和R7在本文中定义。本文提供的某些化合物具有有效的抗细菌，抗原生动物或抗真菌活性，并且对于治疗MRSA感染特别有效。本发明还提供药物组合物，含有羟基噻吩并喹啉与一种或多种其它活性剂的药物组合物，以及通过向有微生物感染的动物施用有效量的羟基噻吩并喹啉酮或相关化合物来治疗动物微生物感染的方法。

6. 发明申请

US20090023730A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION 失效
标题翻译：取代的芳基乙二醇和相关化合物; VIRAL REPLICATION的抑制剂
公开(公告)号：US20090023730A1
公开(公告)日：2009-01-22
申请号：US12036728
申请日：2008-02-25
申请人： Avinash Phadke , Dawei Chen , Milind Deshpande , Andrew Thurkauf , Xiangzhu Wang , Yiping Shen , Cuixian Liu , Jesse Quinn , Junko Ohkanda , Shouming Li
发明人： Avinash Phadke , Dawei Chen , Milind Deshpande , Andrew Thurkauf , Xiangzhu Wang , Yiping Shen , Cuixian Liu , Jesse Quinn , Junko Ohkanda , Shouming Li
IPC分类号： A61K31/5377 , C07C69/00 , A61K31/216 , C07D213/02 , A61K31/44 , C07D295/00 , A61K31/5375 , C07D285/06 , A61K31/433 , C07D241/36 , A61K31/498 , C07D211/06 , A61K31/445 , C07D239/02 , A61K31/505 , C07D215/00 , A61K31/47 , C07D471/02 , A61P31/12 , A61K31/53 , C07D253/06 , A61K31/437 , C07D401/02 , A61K31/496 , C07D487/02 , A61K31/519 , C07D413/02
CPC分类号： C07D295/15 , C07C335/26 , C07D211/22 , C07D211/46 , C07D211/60 , C07D211/64 , C07D211/78 , C07D213/56 , C07D213/82 , C07D215/54 , C07D231/14 , C07D233/54 , C07D233/64 , C07D233/90 , C07D237/24 , C07D239/28 , C07D241/24 , C07D241/44 , C07D249/06 , C07D253/07 , C07D261/18 , C07D263/34 , C07D263/58 , C07D265/30 , C07D271/12 , C07D277/56 , C07D277/68 , C07D285/06 , C07D307/68 , C07D307/84 , C07D307/85 , C07D309/38 , C07D311/58 , C07D333/38 , C07D401/04 , C07D401/12 , C07D405/04 , C07D409/04 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D417/14 , C07D419/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D495/04 , C07D513/04
摘要： The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A1, A2, R1, R2, V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antiviral activity. The invention particularly provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents.The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease.Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.
摘要翻译：本发明提供式I的化合物和药学上可接受的盐，其中变量A1，A2，R1，R2，V，W，X，Y和Z在本文中定义。某些本文所述的具有强抗病毒活性的式I化合物。本发明特别提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式I化合物。本发明还提供含有一种或多种式I化合物或这些化合物的盐，溶剂化物或酰化前药以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。本发明还包括通过向这些患者施用一定量的有效减少疾病或病症的体征或症状的式I化合物来治疗患有某些感染性疾病的患者的方法。这些传染病包括病毒感染，特别是HCV感染。本发明特别包括治疗患有感染性疾病的人类患者的方法，还包括治疗其它动物（包括患有传染病的家畜和驯养的伴侣动物）的方法。治疗方法包括给予式I化合物作为单一活性剂或将一种式I化合物与一种或多种其它治疗剂组合施用。

7. 发明授权

US07476686B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication 失效
标题翻译：取代的芳基硫脲和相关化合物; 病毒复制抑制剂
公开(公告)号：US07476686B2
公开(公告)日：2009-01-13
申请号：US11015300
申请日：2004-12-17
申请人： Dawei Chen , Milind Deshpande , Andrew Thurkauf , Avinash Phadke , Xiangzhu Wang , Yiping Shen , Cuixian Liu , Jesse Quinn , Junko Ohkanda , Shouming Li
发明人： Dawei Chen , Milind Deshpande , Andrew Thurkauf , Avinash Phadke , Xiangzhu Wang , Yiping Shen , Cuixian Liu , Jesse Quinn , Junko Ohkanda , Shouming Li
IPC分类号： A61K31/44 , C07D213/46
CPC分类号： C07D209/48 , C07C335/26 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D207/12 , C07D207/16 , C07D207/34 , C07D207/416 , C07D209/42 , C07D211/14 , C07D211/62 , C07D211/70 , C07D211/86 , C07D213/64 , C07D213/65 , C07D213/81 , C07D215/06 , C07D215/48 , C07D217/04 , C07D231/14 , C07D233/42 , C07D233/90 , C07D239/26 , C07D241/24 , C07D241/44 , C07D249/06 , C07D257/04 , C07D261/18 , C07D263/34 , C07D263/57 , C07D271/08 , C07D271/12 , C07D277/56 , C07D277/66 , C07D277/68 , C07D285/06 , C07D295/135 , C07D295/15 , C07D307/52 , C07D307/68 , C07D307/85 , C07D311/24 , C07D311/66 , C07D317/66 , C07D319/20 , C07D333/20 , C07D333/34 , C07D333/38 , C07D333/70 , C07D405/04 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D487/04 , C07D495/04
摘要： The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A1, A2, R1, R2, V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antiviral activity. The invention particularly provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease.Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.
摘要翻译：本发明提供式I的化合物和药学上可接受的盐，其中变量A1，A2，R1，R2，V，W，X，Y和Z在本文中定义。某些本文所述的具有强抗病毒活性的式I化合物。本发明特别提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式I化合物。本发明还提供含有一种或多种式I化合物或这些化合物的盐，溶剂化物或酰化前药以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。本发明还包括通过向这些患者施用一定量的有效减少疾病或病症的体征或症状的式I化合物来治疗患有某些感染性疾病的患者的方法。这些传染病包括病毒感染，特别是HCV感染。本发明特别包括治疗患有感染性疾病的人类患者的方法，还包括治疗其它动物（包括患有传染病的家畜和驯养的伴侣动物）的方法。治疗方法包括给予式I化合物作为单一活性剂或将一种式I化合物与一种或多种其它治疗剂组合施用。

8. 发明授权

US07094807B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication 失效
标题翻译：取代的芳基硫脲和相关化合物; 病毒复制抑制剂
公开(公告)号：US07094807B2
公开(公告)日：2006-08-22
申请号：US10716175
申请日：2003-11-18
申请人： Dawei Chen , Milind Deshpande , Andrew Thurkauf , Avinash Phadke , Xiangzhu Wang , Yiping Shen , Cuixian Liu , Jesse Quinn , Junko Ohkanda , Shouming Li
发明人： Dawei Chen , Milind Deshpande , Andrew Thurkauf , Avinash Phadke , Xiangzhu Wang , Yiping Shen , Cuixian Liu , Jesse Quinn , Junko Ohkanda , Shouming Li
IPC分类号： A61K31/17 , C07C335/02
CPC分类号： C07D209/48 , C07C335/26 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D207/12 , C07D207/16 , C07D207/34 , C07D207/416 , C07D209/42 , C07D211/14 , C07D211/62 , C07D211/70 , C07D211/86 , C07D213/64 , C07D213/65 , C07D213/81 , C07D215/06 , C07D215/48 , C07D217/04 , C07D231/14 , C07D233/42 , C07D233/90 , C07D239/26 , C07D241/24 , C07D241/44 , C07D249/06 , C07D257/04 , C07D261/18 , C07D263/34 , C07D263/57 , C07D271/08 , C07D271/12 , C07D277/56 , C07D277/66 , C07D277/68 , C07D285/06 , C07D295/135 , C07D295/15 , C07D307/52 , C07D307/68 , C07D307/85 , C07D311/24 , C07D311/66 , C07D317/66 , C07D319/20 , C07D333/20 , C07D333/34 , C07D333/38 , C07D333/70 , C07D405/04 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D487/04 , C07D495/04
摘要： The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A1, A2, R1, R2, V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antiviral activity. The invention particularly provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease.Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.
摘要翻译：本发明提供式I的化合物和药学上可接受的盐，其中变量A 1，A 2，R 1，R 2， / SUB>，V，W，X，Y和Z在本文中定义。某些本文所述的具有强抗病毒活性的式I化合物。本发明特别提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式I化合物。本发明还提供含有一种或多种式I化合物或这些化合物的盐，溶剂化物或酰化前药以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。本发明还包括通过向这些患者施用一定量的有效减少疾病或病症的体征或症状的式I化合物来治疗患有某些感染性疾病的患者的方法。这些传染病包括病毒感染，特别是HCV感染。本发明特别包括治疗患有感染性疾病的人类患者的方法，还包括治疗其它动物（包括患有传染病的家畜和驯养的伴侣动物）的方法。治疗方法包括给予式I化合物作为单一活性剂或将一种式I化合物与一种或多种其它治疗剂组合施用。

9. 发明授权

US09125904B1 Biphenyl imidazoles and related compounds useful for treating HCV infections 有权
标题翻译：联苯咪唑和可用于治疗HCV感染的相关化合物
公开(公告)号：US09125904B1
公开(公告)日：2015-09-08
申请号：US13105504
申请日：2011-05-11
申请人： Jason Allan Wiles , Venkat Gadhachanda , Dawei Chen , Qiuping Wang , Akihiro Hashimoto , Godwin Pais , Xiangzhu Wang , Milind Deshpande , Avinash Phadke
发明人： Jason Allan Wiles , Venkat Gadhachanda , Dawei Chen , Qiuping Wang , Akihiro Hashimoto , Godwin Pais , Xiangzhu Wang , Milind Deshpande , Avinash Phadke
IPC分类号： A61K31/44 , A61K31/47 , A61K38/05 , A61K31/439 , A61K31/4709
CPC分类号： A61K31/439 , A61K31/4709 , A61K38/05 , A61K38/55 , A61K31/436 , A61K2300/00
摘要： Biphenyl imidazoles and related compounds of Formula I, useful as antiviral agents, are provided herein. Pharmaceutical compositions containing a compound of Formula I, together with a second active agent, such as an NS3a protease inhibitor are provided herein. Methods for treating viral infections, including Hepatitis C infections, are included herein by providing a compound of Formula I together with an additional active agent. In certain embodiments the additional active agent is an NS3a protease inhibitor.
摘要翻译：本文提供联苯基咪唑和可用作抗病毒剂的式I的相关化合物。本文提供了含有式I化合物的药物组合物，以及第二活性剂，例如NS3a蛋白酶抑制剂。本文通过提供式I化合物与另外的活性剂一起包括治疗病毒感染（包括丙型肝炎感染）的方法。在某些实施方案中，另外的活性剂是NS3a蛋白酶抑制剂。

10. 发明申请

US20120302538A1 SUBSITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS 有权
标题翻译：用于治疗HCV感染的有用的二醇，环磷酰胺，异黄酮，异黄酮，异黄酮和金属
公开(公告)号：US20120302538A1
公开(公告)日：2012-11-29
申请号：US13482558
申请日：2012-05-29
申请人： Jason Allan Wiles , Qiuping Wang , Akihiro Hashimoto , Godwin Pais , Xiangzhu Wang , Venkat Gadhachanda , Avinash Phadke , Milind Deshpande , Dawei Chen
发明人： Jason Allan Wiles , Qiuping Wang , Akihiro Hashimoto , Godwin Pais , Xiangzhu Wang , Venkat Gadhachanda , Avinash Phadke , Milind Deshpande , Dawei Chen
IPC分类号： A61K31/4178 , A61K31/4184 , C07F17/02 , A61P31/14 , C07D471/08 , A61K31/439 , A61K31/496 , C07D403/14 , A61K31/555
CPC分类号： A61K31/4184 , A61K9/0053 , A61K9/20 , A61K31/4178 , A61K31/422 , A61K31/427 , A61K31/439 , A61K31/454 , A61K31/496 , A61K31/555 , A61K45/06 , A61K2300/00 , C07D209/42 , C07D401/14 , C07D403/04 , C07D403/14 , C07D413/14 , C07D417/14 , C07D453/06 , C07D471/08 , C07D491/10 , C07D491/113 , C07D519/00 , C07F5/025 , C07F15/02 , C07F17/02
摘要： The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D (Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/ and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.
摘要翻译：本公开提供了可用作抗病毒剂的式I D-M-D（式I）的取代的阿片，环戊烷，异烟肼，杂异烟肼，杂异烟草和金属茂。在本文公开的某些实施方案中，M是基团-P-A-P-，其中A是本文公开的某些取代的阿氨苯酯，环戊烷，异烟肼，杂异烟肼，杂异烟草和金属茂是有效和/或选择性的病毒复制抑制剂，特别是丙型肝炎病毒复制。本公开内容还提供药物组合物和/或含有一种或多种取代的阿利膦，环戊二烯，异aph烷，异han嗪，杂异烟草和金属茂的药物组合物和药学上可接受的载体。通过本公开提供了治疗病毒感染的方法，包括丙型肝炎病毒感染。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式